Faron Pharmaceuticals Oy (LON:FARN - Get Free Report)'s stock price passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 216.86 ($2.98) and traded as low as GBX 185 ($2.54). Faron Pharmaceuticals Oy shares last traded at GBX 194.50 ($2.67), with a volume of 20,604 shares traded.
Faron Pharmaceuticals Oy Price Performance
The company has a 50-day moving average of GBX 216.46 and a 200 day moving average of GBX 198.55. The company has a quick ratio of 1.09, a current ratio of 1.45 and a debt-to-equity ratio of 922.55. The stock has a market capitalization of £280.45 million, a PE ratio of -5.59 and a beta of 0.36.
Insider Transactions at Faron Pharmaceuticals Oy
In other news, insider Markku Jalkanen sold 600,000 shares of the company's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of GBX 310 ($4.26), for a total transaction of £1,860,000 ($2,555,998.35). 31.82% of the stock is currently owned by company insiders.
About Faron Pharmaceuticals Oy
(
Get Free Report)
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
See Also
Before you consider Faron Pharmaceuticals Oy, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Faron Pharmaceuticals Oy wasn't on the list.
While Faron Pharmaceuticals Oy currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
